ABSTRACT
Objective:To investigate the influence of single nucleotide polymorphisms (SNP ) of cytidine deaminase (CDA)in the curative effect of gemcitabine,and to clarify the correlation of CDA SNP with the clinical prognosis of the advanced non-small cell lung cancer (NSCLC)patients.Methods:CDA 79A>C gene was detected by Sequenom Massarray Genotype System among 93 patients with advanced NSCLC who received chemotherapy of gemcitabine.The associations between CDA 79A>C polymorphisms and progression free survival (PFS)and overall survival (OS)were estimated using Kaplan-meier methods and Log-rank test for univariate analysis, and COX proportional hazards model was used for multivariate analysis.Results:There was no significant correlation between the CDA 79A>C SNPs with the clinical and pathological characteristics of NSCLC patients.The median PFS in the patients with wild genotype A/A was 9.3 months, while the median PFS in the patients with mutant genotype A/C and C/C was 11 months;there was no significant difference between them (P=0.061).The median OS in the patients with wild genotype A/A was 2 1.7 months, and the median OS of the patients with mutant genotype was 22.1 months;there was no significant difference between them (P=0.513).Conclusion:CDA 79A>C SNPs can prolong the PFS of the NSCLC patients,but it does not affect the OS of the patients.